Previous 10 | Next 10 |
2024-02-09 06:45:00 ET Diabetes and weight-loss medicines surged in popularity last year. Few garnered nearly as much attention as Ozempic, a therapy marketed by Denmark-based biotech giant Novo Nordisk . Ozempic addresses a real problem. Diabetes and obesity have been on the rise for d...
2024-02-06 15:27:22 ET More on Veru Seeking Alpha’s Quant Rating on Veru Historical earnings data for Veru Financial information for Veru Read the full article on Seeking Alpha For further details see: Veru eyes better weight loss drugs as ...
2024-02-06 06:45:00 ET For moves that don't improve the underlying strength of a company's business, stock splits garner a lot of attention, at least when conducted by prominent corporations. In part, that's because they make it easier for investors on a budget to purchase a single share. S...
2024-02-02 12:43:50 ET Summary Regeneron returned to topline growth in 2023 and this has led to the company's valuation rising to my expected EV/revenue range. The company is making significant investments in the obesity space, focusing on preserving lean mass and reducing fat mas...
2024-02-02 11:59:04 ET Regeneron Pharmaceuticals, Inc. (REGN) Q4 2023 Earnings Conference Call February 2, 2024 8:30 AM ET Company Participants Ryan Crowe - Senior Vice President, Investor Relations Leonard Schleifer - President and Chief Executive Officer George...
2024-02-02 07:17:52 ET More on Regeneron Regeneron Pharmaceuticals Inc. (REGN) 42nd Annual JPMorgan Healthcare Conference - (Transcript) Why I Expect Regeneron To Keep Delivering For Investors In 2024 (Upgrade) Regeneron Pharmaceuticals Inc. (REGN) American Society o...
2024-02-02 07:13:00 ET More on Regeneron Pharmaceuticals Regeneron Pharmaceuticals Inc. (REGN) 42nd Annual JPMorgan Healthcare Conference - (Transcript) Why I Expect Regeneron To Keep Delivering For Investors In 2024 (Upgrade) Regeneron Pharmaceuticals Inc. (REGN) Am...
2024-02-02 06:32:56 ET More on Regeneron Pharmaceuticals Why I Expect Regeneron To Keep Delivering For Investors In 2024 (Upgrade) 2seventy stock rises as Regeneron acquires R&D assets Read the full article on Seeking Alpha For further details see: Re...
Atlas Lithium Corporation (ATLX) is expected to report $-0.47 for Q4 2023 Capital Product Partners L.P. (CPLP) is expected to report $0.7 for Q4 2023 WisdomTree Inc. (WT) is expected to report $0.11 for Q4 2023 Mitsubishi Corporation (MSBHF) is expected to report for Q3 2024 C3is ...
TARRYTOWN, N.Y., Feb. 02, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the European Medicines Agency (EMA) has accepted for review the Marketing Authorization Application (MAA) for linvoseltamab to treat adult patients with relapsed/refrac...
News, Short Squeeze, Breakout and More Instantly...
Regeneron Pharmaceuticals Inc. Company Name:
REGN Stock Symbol:
NASDAQ Market:
Regeneron Pharmaceuticals Inc. Website:
A look at the top 10 most actives in the United States Qualigen Therapeutics Inc. (QLGN) rose 111.4% to $0.4341 on volume of 412,713,755 shares Maxeon Solar Technologies Ltd. (MAXN) fell 1.3% to $0.2375 on volume of 280,800,277 shares NVIDIA Corporation (NVDA) rose 1.4% to $129.24 on volu...
2024-07-12 11:00:05 ET Trung Huynh from UBS issued a price target of $1,250.00 for REGN on 2024-07-12 10:18:00. The adjusted price target was set to $1,250.00. At the time of the announcement, REGN was trading at $1092.3075. The overall price target consensus is at $902....
A look at the top 10 most actives in the United States Maxeon Solar Technologies Ltd. (MAXN) rose 3.6% to $0.2493 on volume of 118,503,418 shares Qualigen Therapeutics Inc. (QLGN) rose 94.8% to $0.4 on volume of 100,863,101 shares AgriFORCE Growing Systems Ltd. (AGRI) rose 20.0% to $0.098...